ATNX - Athenex, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Athenex, Inc.

1001 Main Street
Suite 600
Buffalo, NY 14203
United States
716-427-2950
http://www.athenex.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees575

Key Executives

NameTitlePayExercisedYear Born
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.Chairman & CEO673.46kN/A1960
Mr. Jeffrey M. YordonCOO & Pres of Athenex Pharmaceutical Division675.24kN/A1949
Dr. Rudolf Kwan M.D., M.B., B.S.Exec. VP & Chief Medical Officer473.38kN/A1953
Mr. Kam-Chung Leung GBS, LLD, OBE, JPStrategic & Bus. Advisor11kN/A1952
Dr. Allen BarnettCo-Founder & Pres EmeritusN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Corporate Governance

Athenex, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.